Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin-Reference-Cited by-同舟云学术

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin

Published:2015-12 Issue:12 Volume:113 Page:1687-1693
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Colmegna B,Uboldi S,Frapolli R,Licandro S A,Panini N,Galmarini C M,Badri Nadia,Spanswick V J,Bingham J P,Kiakos Konstantinos,Erba E,Hartley J A,D'Incalci M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2015407.pdf

Reference36 articles.

1. Clingen PH, Wu JY, Miller J, Mistry N, Chin F, Wynne P, Prise KM, Hartley JA (2008) Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 76: 19–27.

2. D'Incalci M, Galmarini CM (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9: 2157–2163.

3. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M (2001) Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92: 583–588.

4. de Laat WL, Jaspers NG, Hoeijmakers JH (1999) Molecular mechanism of nucleotide excision repair. Genes Dev 13: 768–785.

5. Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM (2009) H2AX: functional roles and potential applications. Chromosoma 118: 683–692.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?;Drug Design, Development and Therapy;2024-06

2. In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedin;Biomedicine & Pharmacotherapy;2024-03

3. Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment—Progresses in Their Use in Combined Cancer Therapy;Molecules;2024-01-09

4. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line;British Journal of Cancer;2023-02-09

5. Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case–control study;International Journal of Gynecologic Cancer;2022-12-23